Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 308, Issue 12, 2015, Pages 1245-1252

  Stone, Matthew L ^a   Sharma, Ashish K ^a   Zhao, Yunge ^a   Charles, Eric J ^a   Huerter, Mary E ^a   Johnston, William F ^a   Kron, Irving L ^a   Lynch, Kevin R ^a   Laubach, Victor E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Barrier function; Inflammation; Invariant natural killer T cells; Lung transplantation; Primary graft dysfunction

Indexed keywords

1 AMINO 3 [4 OCTYLPHENYL]CYCLOPENTYL)METHANOL; CYTOKINE; FINGOLIMOD; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PROTECTIVE AGENT; PROTEIN P40; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYCLOPENTANE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LYSOPHOSPHOLIPID; PROPANEDIOL DERIVATIVE; RAC-((1R*,3S*)-1-AMINO-3-(4-OCTYLPHENYL)CYCLOPENTYL)METHANOL HYDROCHLORIDE; S1PR1 PROTEIN, MOUSE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; LUNG ARTERY PRESSURE; LUNG FUNCTION; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER T CELL; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REPERFUSION INJURY; TISSUE LEVEL; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; LUNG INJURY; LUNG LAVAGE; METABOLISM;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CYCLOPENTANES; CYTOKINES; FLOW CYTOMETRY; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LUNG INJURY; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; REPERFUSION INJURY; SPHINGOSINE;

EID: 84932139889     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00302.2014     Document Type: Article

References (50)

1. Anselmo DM, Amersi FF, Shen XD, Gao F, Katori M, Lassman C, Ke B, Coito AJ, Ma J, Brinkmann V, Busuttil RW, Kupiec-Weglinski JW, Farmer DG. FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am J Transplant 2: 843–849, 2002
2. Awad AS, Ye H, Huang L, Li L, Foss FW Jr, Macdonald TL, Lynch KR, Okusa MD. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 290: F1516–F1524, 2006
3. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453–21457, 2002
4. Camp SM, Bittman R, Chiang ET, Moreno-Vinasco L, Mirzapoiazova T, Sammani S, Lu X, Sun C, Harbeck M, Roe M, Natarajan V, Garcia JG, Dudek SM. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)- 1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther 331: 54–64, 2009
5. Chiyo M, Iwata T, Webb TJ, Vasko MR, Thompson EL, Heidler KM, Cummings OW, Yoshida S, Fujisawa T, Brand DD, Wilkes DS. Silencing S1P1 receptors regulates collagen-V reactive lymphocyte-mediated immunobiology in the transplanted lung. Am J Transplant 8: 537–546, 2008
6. Christie JD, Edwards LB, Kucheryavaya AY, Aurora P, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report–2010. J Heart Lung Transplant 29: 1104–1118, 2010
7. de Perrot M, Young K, Imai Y, Liu M, Waddell TK, Fischer S, Zhang L, Keshavjee S. Recipient T cells mediate reperfusion injury after lung transplantation in the rat. J Immunol 171: 4995–5002, 2003
8. Ding R, Han J, Tian Y, Guo R, Ma X. Sphingosine-1-phosphate attenuates lung injury induced by intestinal ischemia/reperfusion in mice: role of inducible nitric-oxide synthase. Inflammation 35: 158–166, 2012
9. Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, Natarajan V, Garcia JG. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 19: 1754–1764, 2007
10. Ephstein Y, Singleton PA, Chen W, Wang L, Salgia R, Kanteti P, Dudek SM, Garcia JG, Jacobson JR. Critical role of S1PR1 and integrin beta4 in HGF/c-Met-mediated increases in vascular integrity. J Biol Chem 288: 2191–2200, 2013
11. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280: 17286–17293, 2005
12. Foss FW Jr, Snyder AH, Davis MD, Rouse M, Okusa MD, Lynch KR, Macdonald TL. Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem 15: 663–677, 2007
13. Fryer RM, Muthukumarana A, Harrison PC, Nodop Mazurek S, Chen RR, Harrington KE, Dinallo RM, Horan JC, Patnaude L, Modis LK, Reinhart GA. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P1) and hypertension (S1P3) in rat. PLoS One 7: e52985, 2012
14. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108: 689–701, 2001
15. Gon Y, Wood MR, Kiosses WB, Jo E, Sanna MG, Chun J, Rosen H. S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc Natl Acad Sci USA 102: 9270–9275, 2005
16. Graeler M, Shankar G, Goetzl EJ. Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. J Immunol 169: 4084–4087, 2002
17. Granton J. Update of early respiratory failure in the lung transplant recipient. Curr Opin Crit Care 12: 19–24, 2006
18. Hirt SW, von Suesskind-Schwendi M, Puehler T, Schmid C, Lehle K. Early administration of FTY720 prevents chronic airway as well as vascular destruction in experimental rat lung transplantation. Transplant Proc 45: 783–786, 2013
19. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 47: 401–407, 2003
20. Hwang SJ, Kim JH, Kim HY, Kim S, Chung DH. FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration. Lab Invest 90: 9–19, 2010
21. Kreisel D, Sugimoto S, Zhu J, Nava R, Li W, Okazaki M, Yamamoto S, Ibrahim M, Huang HJ, Toth KA, Ritter JH, Krupnick AS, Miller MJ, Gelman AE. Emergency granulopoiesis promotes neutrophil-dendritic cell encounters that prevent mouse lung allograft acceptance. Blood 118: 6172–6182, 2011
22. Lapar DJ, Hajzus VA, Zhao Y, Lau CL, French BA, Kron IL, Sharma AK, Laubach VE. Acute hyperglycemic exacerbation of lung ischemiareperfusion injury is mediated by receptor for advanced glycation endproducts signaling. Am J Respir Cell Mol Biol 46: 299–305, 2012
23. Levkau B, Hermann S, Theilmeier G, van der Giet M, Chun J, Schober O, Schafers M. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 110: 3355–3359, 2004
24. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 510: 58–67, 2014
25. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346–349, 2002
26. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355–360, 2004
27. Melendez AJ. Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets. Biochim Biophys Acta 1784: 66–75, 2008
28. Muller HC, Hocke AC, Hellwig K, Gutbier B, Peters H, Schonrock SM, Tschernig T, Schmiedl A, Hippenstiel S, N’Guessan PD, Rosseau S, Suttorp N, Witzenrath M. The sphingosine-1 phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. Pulm Pharmacol Ther 24: 377–385, 2011
29. Murakami A, Takasugi H, Ohnuma S, Koide Y, Sakurai A, Takeda S, Hasegawa T, Sasamori J, Konno T, Hayashi K, Watanabe Y, Mori K, Sato Y, Takahashi A, Mochizuki N, Takakura N. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol Pharmacol 77: 704–713, 2010
30. Okazaki M, Kreisel F, Richardson SB, Kreisel D, Krupnick AS, Patterson GA, Gelman AE. Sphingosine 1-phosphate inhibits ischemia reperfusion injury following experimental lung transplantation. Am J Transplant 7: 751–758, 2007
31. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H, Pearse D, Tuder RM, Garcia JG. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 169: 1245–1251, 2004
32. Ross SD, Tribble CG, Gaughen JR Jr, Shockey KS, Parrino PE, Kron IL. Reduced neutrophil infiltration protects against lung reperfusion injury after transplantation. Ann Thorac Surg 67: 1428–1433, 1999
33. Sawicka E, Zuany-Amorim C, Manlius C, Trifilieff A, Brinkmann V, Kemeny DM, Walker C. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol 171: 6206–6214, 2003
34. Schroder M, Richter C, Juan MH, Maltusch K, Giegold O, Quintini G, Pfeilschifter JM, Huwiler A, Radeke HH. The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen. Mol Immunol 48: 1139–1148, 2011
35. Schulze T, Golfier S, Tabeling C, Rabel K, Graler MH, Witzenrath M, Lipp M. Sphingosine-1-phosphate receptor 4 (S1P4) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model. FASEB J 25: 4024–4036, 2011
36. Sharma AK, LaPar DJ, Stone ML, Zhao Y, Kron IL, Laubach VE. Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury. Am J Transplant 13: 2255–2267, 2013
37. Sharma AK, LaPar DJ, Zhao Y, Li L, Lau CL, Kron IL, Iwakura Y, Okusa MD, Laubach VE. Natural killer T cell-derived IL-17 mediates lung ischemia-reperfusion injury. Am J Respir Crit Care Med 183: 1539–1549, 2011
38. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 43: 662–673, 2010
39. Sobel K, Menyhart K, Killer N, Renault B, Bauer Y, Studer R, Steiner B, Bolli MH, Nayler O, Gatfield J. Sphingosine-1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling. J Biol Chem 288: 14839–14851, 2013
40. Stammberger U, Gaspert A, Hillinger S, Vogt P, Odermatt B, Weder W, Schmid RA. Apoptosis induced by ischemia and reperfusion in experimental lung transplantation. Ann Thorac Surg 69: 1532–1536, 2000
41. Sun X, Singleton PA, Letsiou E, Zhao J, Belvitch P, Sammani S, Chiang ET, Moreno-Vinasco L, Wade MS, Zhou T, Liu B, Parastatidis I, Thomson L, Ischiropoulos H, Natarajan V, Jacobson JR, Machado RF, Dudek SM, Garcia JG. Sphingosine-1-phosphate receptor- 3 is a novel biomarker in acute lung injury. Am J Respir Cell Mol Biol 47: 628–636, 2012
42. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 79: 1553–1560, 2005
43. Trifilieff A, Fozard JR. Sphingosine-1-phosphate-induced airway hyperreactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor. J Pharmacol Exp Ther 342: 399–406, 2012
44. Wilkerson BA, Argraves KM. The role of sphingosine-1-phosphate in endothelial barrier function. Biochim Biophys Acta 1841: 1403–1412, 2014
45. Xu Y, Krause A, Limberis M, Worgall TS, Worgall S. Low sphingosine- 1-phosphate impairs lung dendritic cells in cystic fibrosis. Am J Respir Cell Mol Biol 48: 250–257, 2013
46. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 160: 5493–5499, 1998
47. Yang Z, Sharma AK, Linden J, Kron IL, Laubach VE. CD4+ T lymphocytes mediate acute pulmonary ischemia-reperfusion injury. J Thorac Cardiovasc Surg 137: 695–702; discussion 702, 2009
48. Yang Z, Sharma AK, Marshall M, Kron IL, Laubach VE. NADPH oxidase in bone marrow-derived cells mediates pulmonary ischemiareperfusion injury. Am J Respir Cell Mol Biol 40: 375–381, 2009
49. Zhao M, Fernandez LG, Doctor A, Sharma AK, Zarbock A, Tribble CG, Kron IL, Laubach VE. Alveolar macrophage activation is a key initiation signal for acute lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol 291: L1018–L1026, 2006
50. Zhu R, Snyder AH, Kharel Y, Schaffter L, Sun Q, Kennedy PC, Lynch KR, Macdonald TL. Asymmetric synthesis of conformationally constrained fingolimod analogs—discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist. J Med Chem 50: 6428–6435, 2007.